Novavax Inc - NVAX STOCK NEWS

Novavax (Nasdaq: NVAX) announced that the Thailand Food and Drug Administration granted Emergency Use Authorization (EUA) for its COVID-19 vaccine, NVX-CoV2373, in individuals aged 18 and older. The vaccine, manufactured by Serum Institute of India under the brand name Covovax™, demonstrated efficacy of 90.4% in the U.S. and Mexico trials and 89.7% in the U.K. trial. These trials indicated a favorable safety profile. Covovax™ is also authorized in several countries and the company aims to provide additional vaccination options to combat COVID-19.

Novavax (Nasdaq: NVAX) announced its request for expanding the conditional marketing authorization of Nuvaxovid™ COVID-19 Vaccine for adolescents aged 12-17 in the EU. This potential approval would make Nuvaxovid the first protein-based COVID-19 vaccine option for this age group in Europe. The submission includes clinical trial data showing 80% efficacy during the Delta variant surge. The vaccine was well-tolerated, with minimal serious adverse events. Novavax aims to increase vaccination rates amid rising COVID-19 cases in Europe and plans to file for regulatory approval in additional markets.

Novavax, Inc. (Nasdaq: NVAX) announced its participation in two ongoing clinical trials evaluating NVX-CoV2373, its COVID-19 vaccine, as a booster. One trial, sponsored by NIAID, will assess boosting regimens after initial vaccination with FDA-approved or authorized vaccines, enrolling 1,130 participants. The second trial in the UAE focuses on individuals previously vaccinated with Sinopharm’s vaccine, targeting around 1,000 participants. Topline results from these studies are anticipated later in 2022, contributing to the understanding of NVX-CoV2373's safety and efficacy in booster scenarios.

Novavax has received emergency use authorization (EUA) for its COVID-19 vaccine, Covovax™, aimed at adolescents aged 12 to 18, in India. This marks the first authorization of a protein-based COVID-19 vaccine for this age group in the country. Data from a Phase 2/3 study indicates Covovax has a reassuring safety profile and is immunogenic. The vaccine is manufactured by Serum Institute of India and represents a significant milestone in immunization efforts. Notably, NVX-CoV2373 has yet to be authorized for use in the U.S.

Novavax, Inc. (Nasdaq: NVAX) has launched two unbranded educational programs, 'We Do Vaccines' and 'Know Our Vax', aimed at raising public awareness about vaccines. The initiative focuses on the importance of vaccination in combating COVID-19 and other infectious diseases. The programs provide educational resources on vaccine types, production, and Novavax's unique technology. Novavax aims to encourage vaccination uptake and improve global health through these efforts. Both programs are accessible via their respective websites.

Novavax (Nasdaq: NVAX) will participate in Cowen's 42nd Annual Healthcare Conference on March 8, 2022, from 9:50 – 10:20 a.m. EST. The session will focus on their recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373. Key company executives, including Filip Dubovsky and John J. Trizzino, will present. A recorded session will be available on the company's website for 90 days post-conference. Novavax is also developing a COVID-influenza combination vaccine currently in clinical trials.

Novavax has received multiple global regulatory authorizations for its COVID-19 vaccine NVX-CoV2373, including from the EU, WHO, and Australia. The company reported $1.1 billion in revenue for 2021, a significant increase from $476 million in 2020, with projected 2022 revenues between $4 billion and $5 billion. The vaccine demonstrated 82.5% efficacy and broad cross-reactivity against variants. While research and development costs surged to $2.5 billion, the company showcased robust cash reserves of $1.5 billion, marking a positive financial position.

Novavax, Inc. (Nasdaq: NVAX) reported findings from an extended analysis of its Phase 3 clinical trial for the protein-based COVID-19 vaccine NVX-CoV2373 in the UK. The data indicates a sustained vaccine efficacy of 82.5% over a six-month period, demonstrating significant protection against both symptomatic and asymptomatic COVID-19. Notably, efficacy against severe disease was reported at 100%. The vaccine maintains a reassuring safety profile, with adverse events reported equally among vaccine and placebo groups. These results support ongoing regulatory submissions and future vaccine distribution efforts.

Novavax, Inc. (Nasdaq: NVAX) will report its fourth quarter and full year 2021 financial results on February 28, 2022, after U.S. markets close. The conference call is scheduled for 4:30 p.m. EST, with a replay available from 7:30 p.m. EST until March 7, 2022. Novavax is focused on next-generation vaccines, including its COVID-19 vaccine, which has received conditional authorization globally. The company is also developing a COVID-seasonal influenza combination vaccine, currently in a Phase 1/2 clinical trial.